CJC-1295 (no DAC) is a growth hormone-releasing hormone (GHRH) analog that has been studied for its ability to stimulate the pituitary gland to increase natural growth hormone (GH) and IGF-1 secretion. Unlike its counterpart with DAC (Drug Affinity Complex), the no-DAC version has a shorter half-life, allowing for more precise control in research settings.
This peptide is of particular interest in research focused on circadian growth hormone pulsatility, cellular repair, metabolic function, and age-related hormone decline. CJC-1295 (no DAC) is often studied in combination with other secretagogues like Ipamorelin for potential synergistic effects.